The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | Hombach Robert J. | Director | Buy(P) | 13K | $18.14 | $236K |
| May 4, 2026 | PureTech Health plc | 10% Owner | Conversion(C) | 3.0M | — | $0 |
| May 4, 2026 | PureTech Health plc | 10% Owner | Conversion(C) | 8.4M | — | $0 |
| May 4, 2026 | PureTech Health plc | 10% Owner | Conversion(C) | 40.0M | — | $0 |
| May 4, 2026 | PureTech Health plc | 10% Owner | Conversion(C) | 965K | — | — |
| May 4, 2026 | PureTech Health plc | 10% Owner | Conversion(C) | 2.7M | — | — |
| May 4, 2026 | PureTech Health plc | 10% Owner | Conversion(C) | 12.7M | — | — |
| May 4, 2026 | Torres Denice | Director | Conversion(C) | 42K | — | $0 |
| May 4, 2026 | Torres Denice | Director | Conversion(C) | 13K | — | — |
| May 4, 2026 | Paul Steven M | Director | Conversion(C) | 211K | — | $0 |
| May 4, 2026 | Paul Steven M | Director | Conversion(C) | 67K | — | — |
| May 4, 2026 | White Lauren | Chief Financial Officer | Conversion(C) | 21K | — | $0 |
| May 4, 2026 | White Lauren | Chief Financial Officer | Conversion(C) | 7K | — | — |
| May 4, 2026 | Loebel Antony | Chief Medical Officer | Conversion(C) | 63K | — | $0 |
| May 4, 2026 | Loebel Antony | Chief Medical Officer | Conversion(C) | 20K | — | — |
| May 4, 2026 | Healy James | Director | Conversion(C) | 2.5M | — | $0 |
| May 4, 2026 | Healy James | Director | Conversion(C) | 6.1M | — | $0 |
| May 4, 2026 | Healy James | Director | Conversion(C) | 804K | — | — |
| May 4, 2026 | Healy James | Director | Conversion(C) | 1.9M | — | — |
| May 4, 2026 | Gladstein Lana | General Counsel | Conversion(C) | 105K | — | $0 |
| May 4, 2026 | Gladstein Lana | General Counsel | Conversion(C) | 34K | — | — |
| May 4, 2026 | ARCH Venture Partners XII, LLC | 10% Owner | Conversion(C) | 2.7M | — | $0 |
| May 4, 2026 | ARCH Venture Partners XII, LLC | 10% Owner | Conversion(C) | 2.5M | — | $0 |
| May 4, 2026 | ARCH Venture Partners XII, LLC | 10% Owner | Buy(P) | 1.1M | $18.00 | $19.8M |
| May 4, 2026 | ARCH Venture Partners XII, LLC | 10% Owner | Conversion(C) | 2.7M | — | — |
| May 4, 2026 | ARCH Venture Partners XII, LLC | 10% Owner | Conversion(C) | 2.5M | — | — |
| May 4, 2026 | Chen Michael Cunyuan | Chief Scientific Officer | Conversion(C) | 11K | — | $0 |
| May 4, 2026 | Chen Michael Cunyuan | Chief Scientific Officer | Conversion(C) | 3K | — | — |
| Apr 30, 2026 | Zohar Daphne | Chief Executive Officer, Director | Grant(A) | 1.5M | — | $0 |
| Apr 30, 2026 | Wheadon David E. | Director | Grant(A) | 12K | — | $0 |
| Apr 30, 2026 | Torres Denice | Director | Grant(A) | 12K | — | $0 |
| Apr 30, 2026 | Peterson Sandra E | Director | Grant(A) | 12K | — | $0 |
| Apr 30, 2026 | Paul Steven M | Director | Grant(A) | 991K | — | $0 |
| Apr 30, 2026 | Paul Steven M | Director | Grant(A) | 12K | — | $0 |
| Apr 30, 2026 | Zohar Daphne | Chief Executive Officer, Director | Grant(A) | 272K | — | $0 |
| Apr 30, 2026 | White Lauren | Chief Financial Officer | Grant(A) | 64K | — | $0 |
| Apr 30, 2026 | Mates Sharon | Director | Grant(A) | 49K | — | $0 |
| Apr 30, 2026 | Hombach Robert J. | Director | Grant(A) | 12K | — | $0 |
| Apr 30, 2026 | Loebel Antony | Chief Medical Officer | Grant(A) | 64K | — | $0 |
| Apr 30, 2026 | Gladstein Lana | General Counsel | Grant(A) | 64K | — | $0 |
| Apr 30, 2026 | Chen Michael Cunyuan | Chief Scientific Officer | Grant(A) | 64K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).